Orion Group's Annual Report for 2011 has been published. The report is available in Finnish at http://ar2011.orion.fi and in English at http://ar2011.orion.fi/en. The Annual Report 2011 is published only as an Online Report.
Orion's Corporate Governance Statement for year 2011, adopted by the Board of Directors, is published as a separate report in Finnish at http://www.orion.fi/en/Orion/Corporate-Governance/ and in English at http://www.orion.fi/en/Orion/Corporate-Governance/.
SVP, Corporate Functions
Attached PDF version:
Orion Corporate Governance Statement 2011.pdf
Orionintie 1A, FI-02200 Espoo
Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
The Group's net sales in 2011 amounted to EUR 918 million. The Company invested EUR 88 million in research and development. At the end of 2011, the Group had about 3,400 employees, of whom about 2,700 worked in Finland and the rest in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.